PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
22-Nov-2023 ABPI response to Autumn Statement 2023 ABPI
22-Nov-2023 Biocair announces US expansion as part of global growth strategy Biocair
22-Nov-2023 The Crick sets 2040 net zero target Francis Crick Institute
22-Nov-2023 Relief Therapeutics Announces CEO Transition Relief Therapeutics Holding SA
22-Nov-2023 DocMorris optimises organisational structure and prepares for e-prescription growth in Germany DocMorris AG
21-Nov-2023 Fresenius Medical Care AG & Co. KGaA: Favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million – 2023 earnings outlook raised Fresenius Medical Care AG & Co. KGaA
21-Nov-2023 Pioneering Belgian project ATHENA paves the way for Real-World Data reuse in research and personalized care. ATHENA
21-Nov-2023 Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing Immix Biopharma, Inc.
21-Nov-2023 iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference iTeos
21-Nov-2023 Immunomodulator II patent granted in Japan Poolbeg Pharma plc
21-Nov-2023 Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics Myricx Bio
21-Nov-2023 European Commission Approves pharmaand GmbH’s Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer pharmaand GmbH
21-Nov-2023 Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board. Eckert & Ziegler Strahlen- und Medizintechnik AG
21-Nov-2023 PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG HUMANWELL PAION AG
21-Nov-2023 Abivax announces the resumption of its liquidity contract ABIVAX
21-Nov-2023 Marinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development Marinomed Biotech AG
21-Nov-2023 Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders Evolva Holding SA
20-Nov-2023 MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction MorphoSys AG
20-Nov-2023 Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction MorphoSys AG
20-Nov-2023 Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib) Astex Pharmaceuticals